Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 17/20 | 0.57 |
| ▸ | AURKA | O14965 | 14/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338834 | 0.91 | AURKA (0.52) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338847 | 0.90 | AURKA (0.53) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL13004257 | 0.87 | AURKB (0.57) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338773 | 0.87 | AURKB (0.60) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL12338787 | 0.85 | AURKB (0.77) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338796 | 0.84 | AURKB (0.57) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338732 | 0.83 | AURKB (0.68) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338835 | 0.83 | AURKA (0.51) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338811 | 0.82 | AURKB (0.67) | AURKBAURKAABL1BCRAURKC | |
| SCHEMBL12338735 | 0.81 | AURKB (0.78) | AURKBAURKAABL1BCRAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382229-B2 | Compounds and methods of use thereof for treating neurodegenerative disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140187540-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012112674-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187540-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, HTT | AURKB 4124/4885AURKA 4696/4885ABL1 4186/4885 |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885ABL1 58/4885 |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885ABL1 58/4885 |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | AURKB 1/4885AURKA 3/4885ABL1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.